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Introduction
Clostridium difficile infections(CDI) epidemiology has
changed: elevation in rate and severity of infection and
increase in disease among outpatients.
Objectives
Aim of study was to evaluate the epidemiology of CDI
in North Tenerife Area.
Methods
This is an epidemiological study performed in the Hospital
Universitario de Canarias a tertiary care institution during
2011-2012. Studied population was outpatients or inpati-
ents attended in this hospital with CDI suspected.
Diagnostic procedures were based in GDH and later
Toxin A/B detection as CDI confirmation in stool samples
by EIA.Medical charts of patient were reviewed to collect:
demographic variables, underlying diseases (diabetes(D),
renal disease(RD), liver disease(LD), respiratory disease
(ReD), cardiopathy(C), neoplasia(N)), ≥3 co-morbidities,
inflammatory boweldisease(IBD), solidorgan transplant
(OST), immunocompromised states(IC), treatment pre-
vious, treatment of CDI, developed to Pseudo-membranous
colitis(PMC), mortality due to CDI. The episodes were
classificated as nosocomial, healthcare associated (HCA),
community, indeterminate, and recurrence.
Results
In 2011/2012 a total 18/45 episodes (17/41 patients) were
diagnosticated. 50/62% were man and 7/22 (39/49%), <65
years.HCA and nosocomial CDI incidence were: 0, 7/1, 7
case/104 patient–day. The services distribution was: Inter-
nal Medicine 6/12(33/27%), Nephrology 6/4 (33/9%),
Hematology 2/5(11/11%). Episodes: Community 4/7 (22/
15%), Nosocomial 14/27(78/60%), HCA 0/6(0/13%),
Indeterminate 0/1(0/2%) and recurrences 0/4 (0/9%). In
Nosocomial the time average between admission and CDI
diagnostic was 10, 6±9, 1/24±29 d. Underlying diseases: C
10/9(55/20%), RD 5/10(27,7/22%), LD 2/4(11/9%), ReD 2/
2(11/4%), N2/10(11/22%). ≥3 co-morbidities 3/3(17/7%).
IBD 1/1(6/2%), OST 7/3(39/6,6%), IC 10/20(55/44%), pre-
vious treatment: Omeprazol 6/10(33/22%), Ranitidine 3/1
(17/2%), Aciclovir 1/2(5,6/4,4%), Carbapenems 6/21(33/
47%), Fluorquinolones 5/13(28/29%), Cephalosporins (3-
4ª) 4/11 (22/24%), Vancomycin(VA) 3/6(17/13%), Amoxi-
cillin-clavunate 2/7(11/16%). CDI Treatment: Metronida-
zole 18/39(100/87%), VA 3/9 (17/20%), developed PMC 2/
5(11/11%), death for CDI 1/0.
Conclusion
In our hospital there has been an increase in nosocomial
CDI adquisition overtime and a high percentage in
young patients. At 2012 OST patients declined and
HCA episodes were increased thus we observed that
CDI is not confined to hospitals.
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